期刊文献+

吡格列酮对2型糖尿病患者微量白蛋白尿影响的观察

Evaluate the effect of pioglitazone on microalbuminuria in type 2 diabetes patients
下载PDF
导出
摘要 目的 研究吡格列酮对2型糖尿病微量白蛋白尿的影响.方法 70例2型糖尿病伴微量白蛋白尿患者随机分成吡格列酮组和对照组,观察两组治疗前后空腹血糖、餐后2 h血糖、尿白蛋白排泄率、尿素氮及肌酐的变化.结果 与治疗前相比,吡格列酮组治疗后空腹血糖和餐后2 h血糖、尿白蛋白排泄率明显降低,差异有统计学意义(P〈0.05);对照组治疗前、后上述指标的差异均无统计学意义(P〉0.05);两组间的差异均有统计学意义(P〈0.05);两组治疗前后尿素氮、肌酐的差异均无统计学意义(P〉0.05).结论 吡格列酮能减少尿微量白蛋白. Objective To evaluate the effect of pioglitazone on microalbuminuria in type 2 diabetes patients. Methods 70 cases of type 2 diabetes patients with microalbuminuria were randomly divided into tbe pioglitazone group and the control group. Changes of fasting and 2 h postprandial blood glucose, urinary albumin excretion rate, urea nitrogen, creatinine were observed in the pioglitazone group and the control group before and after the trial. Results The fasting and 2 h postprandial blood glucose,urinary albumin excretion rate decreased obviously after treatment in the pioglitazone group (P 〈 0. 05 ). There was no significant difference in the control group( P 〉 0. 05 ). There were significant differ- ences between the pioglitazone group and the control group (P 〈 0. 05 ). There was no significant difference in the level of urea nitrogen, creatnine after treatment in both groups( P 〉 0. 05 ). Conclusion Pioglitazone can significantly reduce microalbuminuria.
机构地区 绵阳市人民医院
出处 《中外医学研究》 2010年第12期30-31,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 吡格列酮 2型糖尿病 尿微量白蛋白 Pioglitazone Typs 2 diabetes Microalbuminuria
  • 相关文献

参考文献2

二级参考文献18

  • 1陆静,刘乃丰,张丽容.葛根素降低糖尿病大鼠血清糖基化终产物水平和单核细胞趋化蛋白1含量[J].中华内分泌代谢杂志,2004,20(3):255-258. 被引量:17
  • 2李世云,孙子林,刘必成,李丽,刘乃丰.糖基化终产物对人肾系膜细胞分泌白介素8的影响[J].江苏医药,2003,29(10):743-744. 被引量:3
  • 3Zilin S,Naifeng L,Bicheng L, et al. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta,2001,313: 69-75.
  • 4Li Shiyun,Sun Zilin, Elevation of serum MCP-1 in patients with diabetes and diabetic nephropathy. Diabetes Res Clin Pract,2002,56 : S156.
  • 5Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism, 2004, 53:1382-1386.
  • 6Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells. J Biol Chem, 2002,277:20309-20315.
  • 7Chiarelli F, Cipollone F, Mohn A, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes, Diabetes Care, 2002,25:1829-1834.
  • 8Sun ZL. AGE induce the expression of monocyte chemoattractant protein-1 in human mesangial cells. Diabetologia, 2002,45:A394.
  • 9Ford ES.Body mass index diabetes and c-reactive protein among US adults[J].Diabetes Care,1999;22:1971-7.
  • 10Pickup JC,Crook MA.Is type 2 diabetes mellitus a disease of the innate immune system[J]? Diabetologia,1998 ;41:1241-8.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部